KURA Stock Forecast: Kura Oncology, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Kura Oncology, Inc. is $28. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Kura Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KURA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KURA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | JP Morgan | Initiates | Overweight | $30 |
| 24 Aug 2026 | Citizens | Reiterates | Market Outperform | $24 |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $36 → $38 |
| 28 July 2026 | Wedbush | Reiterates | Outperform | $36 |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | $24 |
| 14 Apr 2026 | Lake Street | Initiates | Buy | — |
| 24 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 13 Mar 2026 | UBS | Maintains | Buy | — |
| 6 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 13 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Jan 2026 | Leerink Partners | Maintains | Outperform | — |
| 24 Nov 2025 | Barclays | Maintains | Overweight | — |
| 14 Nov 2025 | UBS | Maintains | Buy | — |
| 14 Nov 2025 | Wedbush | Maintains | Outperform | — |
| 20 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Oct 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 30 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Sept 2025 | Guggenheim | Initiates | Neutral | — |
| 11 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 26 June 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KURA.
This page is one stock. Monday covers all of them.
KURA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KURA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Kura Oncology, Inc. returned −37.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KURA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 8.4×
- Price / book
- 37.3×
- EV / EBITDA
- —
Cheaper than 13% of US stocks
Cheaper than 2% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 98.8%
- Operating margin
- —
- Net margin
- —
Higher than 99% of US stocks
- Return on equity
- −224.9%
- Return on assets
- −32.2%
- Dividend yield
- —
Higher than 6% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kura Oncology, Inc. has a market value of $675.3M and an enterprise value of $209.0M.
Revenue in the twelve months to 30 June 2026: $77.2M. The latest quarter grew 36.5% year on year.
Net income over the same four quarters: −$296.8M, a −384.3% net margin.
Diluted earnings per share, trailing twelve months: −$3.37.
Free cash flow in the twelve months to 30 June 2026: −$117.4M.
Kura Oncology, Inc. employs 260 people — $297K of revenue per employee.
Data provided by Twelve Data
KURA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KURA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Kura Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KURA
What is the KURA stock price forecast for 2026-2027?
The median 12-month analyst price target for Kura Oncology, Inc. is $28, with estimates ranging from $15 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KURA stock a buy right now?
Of the 16 analysts covering Kura Oncology, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kura Oncology, Inc. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KURA?
As at 21 Nov 2026, Kura Oncology, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
Will KURA stock go up?
No one can know that. What the data says: the median 12-month target from 16 analysts is $28, and Ticker Nerd's factor model ranks Kura Oncology, Inc. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KURA stock forecast for 2030?
No analyst covering Kura Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $76 over the next 12 months.
How has KURA stock performed over the past year?
Kura Oncology, Inc. returned -37.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kura Oncology, Inc. do?
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected solid tumors.
About Kura Oncology, Inc.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected solid tumors. Its pipeline includes small-molecule drug candidates such as ziftomenib, tipifarnib, and KO-2806, which are being evaluated in clinical development for genetically defined patient populations. The company’s work combines drug discovery, biomarker-driven research, and clinical testing to support targeted treatment approaches in oncology. Based in San Diego, California, Kura Oncology operates as a focused biotechnology company within the broader cancer therapeutics market, contributing to the development of specialized therapies for patients with high unmet medical need.
CEO Dr. Troy Edward Wilson J.D., Ph.D. · 260 employees · United States · https://www.kuraoncology.com